Results 41 to 50 of about 4,153 (212)
ESC Heart Failure, 2020 Aims Duchenne muscular dystrophy (DMD) is an X‐linked inherited disease due to dystrophin deficiency causing skeletal and cardiac muscle dysfunction. Affected patients lose ambulation by age 12 and usually die in the second to third decades of life from ...
Jeovanna Lowe +13 more
doaj +1 more source
ESC Heart Failure, 2021 Aims In post‐menopausal women, incidence of heart failure with preserved ejection fraction is higher than in men. Hormonal replacement therapies did not demonstrate benefits.
Marie Pieronne‐Deperrois +16 more
doaj +1 more source
New Diabetes Therapies and Diabetic Kidney Disease Progression:the Role of SGLT-2 Inhibitors [PDF]
, 2018 Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease.
Dekkers, Claire C. J. +2 more
core +2 more sources
Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) [PDF]
, 2023 Chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) represents a major public health issue; it develops in about 30%–40% of patients with diabetes mellitus and is the most common cause of CKD worldwide. Patients with CKD and T2D are at
Alexandrou, Maria-Eleni +11 more
core +2 more sources
Steroidal or Non-Steroidal MRAs: Should We Still Enable RAASi Use Through K Binders? [PDF]
, 2022 Renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) are important interventions to improve outcomes in patients with chronic kidney disease and heart failure, but their use is limited in some patients
Gregg, L Parker, Navaneethan, Sankar D
core +2 more sources
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease [PDF]
, 2021 Mineralocorticoid receptor antagonists (MRAs) are key agents in guideline-oriented drug therapy for cardiovascular diseases such as chronic heart failure with reduced ejection fraction and resistant hypertension.
Bakris, George L. +2 more
core +1 more source
Frontiers in MedicineBackgroundAlthough current guidelines have recommended finerenone as a first-line agent for patients with diabetic kidney disease (DKD), it is unclear what effect finerenone has on all-cause and cardiovascular mortality.
Zixuan Zhang +4 more
doaj +1 more source
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial [PDF]
, 2019 Background: Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease.
Agarwal R. +10 more
core +1 more source
Renin–angiotensin system blockade: Finerenone
Néphrologie & Thérapeutique, 2017 Finerenone is a novel selective nonsteroidal mineralocorticoid receptor antagonist. Results in preclinical studies showed that lower doses of finerenone were needed to achieve similar cardiorenal protective effects compared to both spironolactone and eplerenone and phase II studies in finerenone in patients with heart failure, type-2 diabetes mellitus ...
Ruilope Urioste, Luis Miguel +1 more
openaire +4 more sources
Renal FailureFinerenone, a novel high-selective aldosterone receptor antagonist, exhibits powerful anti-inflammatory and antifibrotic effects in previous researches. The aim of our study was to investigate of it on peritoneal fibrosis.
Dandan Chen +8 more
doaj +1 more source